Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
Злокачественное новообразование сосудистой оболочки
Balkhi, S.; Bilato, G.; De LermaBarbaro,A. et al. 
PDF
Vaccines 2025, 13, 69.
Masao Hashimoto, Suresh S. Ramalingam, Ra fi Ahmed. PDF
Trends in cancer. – 2024. – V. 10, Is. 4, Pages 332-346 . DOI: 10.1016/j.trecan.2023.11.008
Kanako Shimizu, Shogo Ueda, Masami Kawamura et al.
Combination of cancer vaccine with CD122-biased IL-2/ anti-IL-2 Ab complex shapes the stem-like effector NK and CD8+ T cells against tumor.Journal for immunotherapy of cancer. – 2023. – V. 11, Is. 7.
Kathryn M. LaPorte, Rosmely Hernandez, Alicia Santos Savio, Thomas R. Malek. PDF
Journal for immunotherapy of cancer . – 2023. – V.11, Is. 6. DOI: 10.1136/jitc-2022-006611
Parisa Shiri Aghbash, Reyhaneh Rasizadeh, Amir Hossein Yari et al.
Interleukin-2 and Oncolytic Virotherapy: A New Perspective in Cancer Therapy.Bentham Science. Anti-Cancer Agents in Medicinal Chemistry, 23(18), 2008-2026 — January 2023 https://doi.org/10.2174/1871520623666230727095154
Veronika Niederlova, Oksana Tsyklauri ,Marek Kovar, Ondrej Stepanek. PDF
Trends in immunology. – 2023. – V. 44, Is. 11, P. 890-901. DOI: 10.1016/j.it.2023.09.003
Hernandez R, Põder J, LaPorte KM, Malek TR.
Engineering IL-2 for immunotherapy of autoimmunity and cancer.Nat Rev Immunol. 2022 Oct;22(10):614-628. doi: 10.1038/s41577-022-00680-w. Epub 2022 Feb 25. PMID: 35217787.
Miro E. Raeber, Dilara Sahin, Ufuk Karakus, Onur Boyman PDF
MedRxiv, December 4, 2022. Doi: https://doi.org/10.1101/2022.12.02.22283042
Гипофракционированная лучевая терапия в сочетании с ингибитором PD-1 Sequential GM-CSF и IL-2 для лечения прогрессирующих рефрактерных солидных опухолей (PRaG2.0).
ICH GCP. Реестр клинических исследований США. Клиническое испытание NCT04892498. – 2022.
Steven A. Rosenberg.
IL-2: The First Effective Immunotherapy for Human Cancer.J Immunol. 2014/ — June 15, 192 (12) 5451-5458; DOI: https://doi.org/10.4049/jimmunol.1490019.
Молчанов О.Е.
Рекомбинантный интерлейкин-2 в лечении злокачественных опухолей различных локализаций. Современное состояние проблемы и перспективные направления исследований.СИНЭЛ: СПб. — 2018. — 32 с.
Tanigawa T, Tanaka H, Kano F, Ueda H, Inafuku S.
Nasal hemangiopericytoma successfully treated with a combination of rIL-2 and extranasal approaches.J Surg Case Rep. 2017 Oct 20;2017(10):rjx202.
Noguchi G., Ota J, Ishigaki H. et al.
A Case of Retroperitoneal Angiosarcoma Effectively Treated With Recombinant interleukin-2.Case Reports Nihon Hinyokika Gakkai Zasshi. 2012 Nov;103(6):697-703. doi: 10.5980/jpnjurol.103.697.
Титов К.С., Волков С.М., Шубина И.Ж., Киселевский М.В. и др. PDF
Внутриперикардиальная иммунотерапия опухолевых перикардитов.
Вестник службы крови России, №1, март 2011.
Исмаилзаде Р.С.
Общая гипертермия в лечении далеко зашедших и рефрактерных форм злокачественных солидных опухолей у детей.Онкологический журнал. — 2007. — № 1 (1) Т.1.
Исмаил-заде Р.С., Белевцев М.В., Потапнев М.П и др.
Иммуномоделирующее действие препаратов интрлейкина-2 и интерферона-альфа в комбинации с сеансами общей гипертермии на этапах интенсивной химиотерапии у детей с далеко зашедшими злокачественными новообразованиями.Медицинская иммунология. — 2006. — Т. 8, № 4. — С. 561-566.
Исмаилзаде Р.С., Белевцев М.В., Потапнев М.П. и др. PDF
Медицинская иммунология. — 2006. — №4. — С. 561-566.
Златник Е.Ю. PDF
Автореферат дисс. докт. мед. наук. – Ростов-на-Дону. — 2003. — 51 с.
Mertens WC, Banerjee D, al-Mutter N et al.
High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets.Cancer Immunol Immunother. 1995 Nov;41(5):271-9. doi: 10.1007/BF01517214. PMID: 8536272.
Zambello R, Trentin L, Cerutti A et al.
Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.Cancer. 1994 Nov 1;74(9):2562-9. doi: 10.1002/1097-0142(19941101)74:9<2562::aid-cncr2820740926>3.0.co;2-1. PMID: 7522954.
Caligiuri MA, Murray C, Robertson MJ et al.
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.J Clin Invest. 1993 Jan;91(1):123-32. doi: 10.1172/JCI116161. PMID: 7678599; PMCID: PMC330005.
Gratama JW, Bruin RJ, Lamers CH et al.
Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.Clin Exp Immunol. 1993 May;92(2):185-93. doi: 10.1111/j.1365-2249.1993.tb03378.x. PMID: 8485906; PMCID: PMC1554808.
Eberlein TJ, Schoof DD.
The role of interleukin-2 in cancer immunotherapy.Compr Ther. 1991 Jan;17(1):49-56. PMID: 2001612.
Farace F, Mathiot C, Brandely M et al.
Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.Clin Exp Immunol. 1990 Nov;82(2):194-9. doi: 10.1111/j.1365-2249.1990.tb05426.x. PMID: 2122928; PMCID: PMC1535125.
Parkinson DR.
Lessons from the clinical trials of interleukin-2.Nat Immun Cell Growth Regul. 1990;9(4):242-52. PMID: 2215513.
Kolitz JE, Wong GY, Welte K et al.
Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.J Biol Response Mod. 1988 Oct;7(5):457-72. PMID: 3263471.
Harel-Bellan A, Bertoglio J, Quillet A et al.
Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.J Immunol. 1986 Apr 1;136(7):2463-9. PMID: 3005412.
Thurman GB, Maluish AE, Rossio JL et al.
Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations.J Biol Response Mod. 1986 Feb;5(1):85-107. PMID: 3514800.
Ortaldo JR, Mason AT, Gerard JP et al.
Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.J Immunol. 1984 Aug;133(2):779-83. PMID: 6203980.
Vose BM, Bonnard GD.
Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. I. The effect of lectin on the proliferative frequency and cytotoxic activity of cultured lymphoid cells.J Immunol. 1983 Feb;130(2):687-93. PMID: 6600251.